The FIGHT trial also showed that around 30% patients with HER2-negative advanced gastric cancer had FGFR2b overexpression or FGFR2 amplification, which supports the development of FGFR2 as a therapeutic target. This evidence concerns the gene FGFR2 and gastric cancer.